Nirman Agri Genetics Ltd (NAGL) — the five-year-old seed startup that bloomed faster than a monsoon weed — has managed to become the talk of Dalal Street, not for its hybrid maize or pest-resistant cotton, but for a SEBI order that hit just when investors were expecting a bonus-cum-split bonanza. From a meteoric rise in revenue (₹270 crore TTM) to an 81.5% stock crash, the company has turned from “agri innovation” to “compliance sensation.”
At ₹70.8 per share, this ₹56.7 crore market cap minnow trades at just 2.01x earnings, a number so low it could be mistaken for a seed discount coupon. The book value of ₹156 makes it one of the rare stocks priced below the soil — 0.45x P/B. Its ROE stands at a juicy 34.3%, and ROCE at 35.2%, numbers that would make even FMCG veterans blush. But beneath this glossy field lies a tangle of corporate drama, promoter exits, and regulatory storms.
Sales have grown 78% year-on-year, PAT up 57%, and debt down to a laughable ₹0.34 crore — practically debt-free. But if SEBI’s 93% fund diversion allegation holds ground, investors may find the company’s cash flow more “fertiliser” than “growth booster.”
So, should one study its hybrid seeds or its hybrid headlines first? Let’s dig deep.
2. Introduction
Once upon a fiscal year, a bright-eyed agri-genetics company from Maharashtra promised to revolutionize Indian farming. With words like “biotechnology,” “hybrid resistance,” and “yield optimisation” sprinkled liberally across its filings, Nirman Agri Genetics sounded like the Monsanto of Nashik.
But in India, every growth story comes with a twist — and this one included a SEBI knock on the door, a bonus proposal frozen mid-air, and a promoter who suddenly found compliance meetings more stressful than droughts.
From selling hybrid corn seeds to selling dreams of ₹120 crore Rabi order books, NAGL sprinted through FY24 and FY25 like a company on steroids. Its EPS shot up from ₹5.01 (FY23) to ₹35.24 (FY25) — that’s a 7x jump in two years. The boardroom looked like a greenhouse of optimism, until October 2025, when SEBI called time-out, alleging that 93% of IPO funds were diverted.
Is this another case of “seed capital” becoming “seed scandal”? Or is Nirman just a misunderstood innovator caught in bureaucratic weeds? Either way, H1FY26 results prove one thing — the company’s numbers still look healthier than its public image.
3. Business Model – WTF Do They Even Do?
Let’s simplify: Nirman Agri Genetics sells hope in packets — the kind farmers bury in soil and investors bury in demat accounts.
Its business revolves around four main activities:
Hybrid Seed Development – breeding disease-resistant, drought-tolerant, high-yielding seeds.
Seed Production – contract farming with partner cultivators.
Marketing & Distribution – branding under “Nirman Agri Genetics” and reaching farmers through retail and Krushi Dham outlets.
Diversified Inputs – expanding into micronutrients, organic fertilizers, and bio-products.
Their “Krushi Dham” project is a mini agri-mall for farmers — think of it as the “Decathlon for Desi Kisans.” It sells everything from seeds to soil testing kits, offers knowledge centers, and even provides financing support. If Walmart met NABARD and decided to do agriculture, this would be it.
In FY24, the company also ventured into fertiliser production and claimed to have 22 new seed varieties licensed by the Maharashtra government. Ambitious? Yes. Over-fertilised with hype? Also yes.
4. Financials Overview
Half-Yearly Results Locked: H1FY26 (Figures in ₹ crore)
Metric
Latest Half-Year (Sep’25)
Same Half-Year Last Year (Sep’24)
Previous Half-Year (Mar’25)
YoY %
QoQ %
Revenue
146
112
124
30.4%
17.7%
EBITDA
15
12
15
25.0%
0.0%
PAT
15
11
14
36.4%
7.1%
EPS (₹)
18.2
14.3
17.0
27.3%
7.1%
Commentary: The numbers look so fertile they could grow crops on their own. Revenue jumped 30% YoY, proving that despite regulatory hiccups, the core business is still photosynthesising cash. EBITDA margins are under mild nitrogen stress — down to 10% (from 11–12%), showing rising cost of goods or “too much urea, too little control.”
EPS at ₹18.2 for H1FY26 annualises to ₹36.4, giving a P/E of 1.9 — the lowest in the seed business. Either the market expects a drought in disclosures or it’s simply not buying what management is sowing.
5. Valuation Discussion – Fair Value Range (Educational Only)
Method 1: P/E Based Approach Industry P/E = 20.1 Company EPS (annualised H1FY26) = ₹36.4 Fair Value Range = ₹36.4 × (10–20) = ₹364 – ₹728
Method 2: EV/EBITDA Approach EV = ₹55.7 Cr EBITDA (TTM) = ₹30 Cr EV/EBITDA = 1.86 Industry median = 8–10× Fair EV range = 8 × 30 to 10 × 30 = ₹240–₹300 Cr Equity Value = ₹240–₹300 Cr – Net Debt (≈₹0 Cr) = ₹240–₹300 Cr Per share = ₹240–₹300 Cr / (0.8 Cr shares) ≈ ₹300–₹375
Method 3: Simplified DCF Assume growth slows to 25% for 3 years, then 5% perpetuity at 12% discount. Approximate fair range = ₹350–₹420
📢 Disclaimer: This fair value range is for educational purposes only and not investment advice. Seeds are unpredictable — in soil or in stocks.
